Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofib 9 May 2023
Chicago-based CTRL Therapeutics, a biotech company developing a cell therapy platform for solid tumors, today announced a $10 million seed financing led by Gene 11 April 2023
BioSenic, a Belgian biotech company specializing in serious autoimmune and inflammatory diseases and cell repair, has named Lieven Huysse, as permanent chief me 3 April 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.